Some people with asthma need to use multiple inhaled medicines each day to keep their symptoms under control. The approval of long-acting, combination inhalers that contain more than one medicine is ...

* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD * TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...

GSK has secured approval in China for Trelegy Ellipta as a maintenance treatment for adults with asthma, adding to its existing indication in COPD and making it the only single inhaler triple therapy ...

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...